Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…Abstract Number: 473 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience
Background/Purpose: Efficacy and safety of anti-TNF in rheumatoid arthritis (RA) management has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…Abstract Number: 474 • 2013 ACR/ARHP Annual Meeting
HM-0523, a Novel Syk Inhibitor Significantly Ameliorates The Severity Of Arthritis In Rodents
Background/Purpose: Spleen tyrosine kinase (SYK) is a key mediator of signaling events downstream of a wide array of receptors important for immune function, including the…Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…Abstract Number: 476 • 2013 ACR/ARHP Annual Meeting
Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Background/Purpose: Remission and low disease activity (LDA) are now more achievable goals in RA. Year 1 data from the head-to-head AMPLE (Abatacept vs Adalimumab Comparison…Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…Abstract Number: 478 • 2013 ACR/ARHP Annual Meeting
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients
Background/Purpose: The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that transduce intracellular signaling for cytokines including interleukins and interferons, and…Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…Abstract Number: 457 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
Background/Purpose: RA is a chronic systemic autoimmune disease resulting in joint inflammation and damage. Despite the current therapies available, only a small percentage of RA…Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…